Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on April 4, 2007, regarding an event that occurred on April 2, 2007. The filing addresses corporate governance changes specifically related to the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The size of the Board of Directors increased from eight to nine directors.
- Director Election: Victor J. Dzau, M.D., was elected as a Class III director to fill the vacancy created by the board expansion.
- Term Details: Dr. Dzau's term is set to expire at the annual meeting of stockholders to be held in 2007.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business operations. Regarding compensation, Dr. Dzau will be compensated as a director pursuant to the Company's existing compensation policy for non-employee directors, as previously described in a Form 8-K filed on September 18, 2006. No risks, contingencies, or unusual items were disclosed in this specific report.
Key Facts for Investor Verification
- Verify the full text of the non-employee director compensation policy referenced from the September 18, 2006 filing.
- Confirm the date of the 2007 annual meeting of stockholders to determine the exact expiration of Dr. Dzau's term.
- Review the Company's proxy statement for the 2007 annual meeting for further details on the board composition and director qualifications.